Singapore: Life Technologies has signed a non-exclusive agreement with iPS Academia Japan for its induced pluripotent st...
A team of chemists and biologists at the Institute of Transformative Bio-Molecules (ITbM), Nagoya University, Japan, hav...
Singapore: Australian infectious disease therapy and vaccine development company, BioDiem, has received allowance of Jap...
Japanese pharmaceutical giant Eisai Co. Ltd. and Nihon Medi-Physics Co. Ltd. have entered into a collaboration agreement...
R-Tech Ueno Ltd, headquartered in Tokyo, has acquired the right to develop and commercialize DE-105 from Santen Pharmace...
Singapore: French biopharmaceutical company, Poxel, an innovative drug developer for type 2 diabetes, has succesfully co...
Singapore: A phase III trial evaluating the efficacy and safety of the addition of Tarceva (erlotinib) tablets to Nexava...
Singapore: US generics major Mylan has entered into a settlement agreement with OSI Pharmaceuticals, a subsidiary of Jap...
Singapore: Advanced wound care and modern wound closure products are gaining an edge over traditional wound dressings in...
Singapore: US-based Biogen, a leading developer of therapies for neurodegenerative diseases has inked a pact with Japan'...
Tokyo: Daiichi Sankyo Company, Limited has obtained approval for partial changes concerning a supplementary indication ...
NASDAQ-listed Synageva BioPharma Corp. has submitted the New Drug Application (NDA) for Kanuma (sebelipase alfa) to the ...
Tokyo: Bayer HealthCare has announced that the company has received approval in Japan for its oral Factor Xa inhibitor X...
With rapid growth of life sciences industry in Asia, we have seen many success stories over the last decade. However, an...
Singapore: Takeda Pharmaceutical has transferred its license agreement with the Japan Health Sciences Foundation (HS Fou...
Singapore: EBD Group, organizer of leading international life science partnering conferences, has announced Medtech Part...
Singapore: Japanese pharmaceutical major Santen Pharmaceutical has decided to sign an agreement with Showa Yakuhin Kakou...
Tokyo: Intercept Pharmaceuticals Inc has announced the results of a 72-week phase II dose ranging trial of obeticholic a...
